Evidence map›Paper›PMID 36158840›Full record

ArticleFrontiers in cardiovascular medicine2022

Alprostadil vs. isosorbide dinitrate in ameliorating angina episodes in patients with coronary slow flow phenomenon: A randomized controlled trial.

Weifeng Zhang, Jinjie Dai, Lan Shen, Yue Jiang, Xiaowen Zheng, Ke Xu, Xiaoxiao Yang, Xiaolei Wang, Ziyong Hao, Yu Zhao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Weifeng ZhangDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jinjie DaiDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Lan ShenDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Yue JiangDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiaowen ZhengDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ke XuDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiaoxiao YangDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiaolei WangDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Ziyong HaoDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Yu ZhaoDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Dong WangDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Lisheng JiangDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xingbiao QiuDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Linghong ShenDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Ben HeDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimum therapy for coronary slow flow phenomenon (CSFP) stays debatable. This study compared the effectiveness of alprostadil with isosorbide dinitrate in alleviating angina episodes in CSFP patients. Methods: In this prospective, randomized controlled study, 102 patients with CSFP without severe coronary artery stenosis that exhibited stable angina were allocated randomly in a ratio of 1:1 to either the alprostadil group (40 μg, three times per day, Results: Baseline characteristics were comparable between the two groups. At 1-month follow-up, patients administered with alprostadil experienced fewer angina episodes [episodes per week, 1 (2) vs. 2 (2), Conclusion: Alprostadil was more effective in ameliorating angina symptoms in CSFP patients than isosorbide dinitrate. Clinical trial registration: [www.chictr.org.cn], identifier [ChiCTR2000033233].

Indexed as

alprostadilangina pectoriscoronary slow flow phenomenonoutcometreatment

Identifiers

PMID36158840
PMCPMC9493040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.